The most common adverse reactions that were associated with discontinuation from clinical trials (causing discontinuation in > 1% of adults and/or > 2% of pediatrics) were nausea, somnolence, sedation, vomiting, dizziness, and akathisia [see ADVERSE REACTIONS, Discontinuations Due to Adverse Reactions].
The data described in this section are derived from a clinical trial database consisting of 9803 adult and pediatric patients exposed to one or more doses of RISPERDAL® for the treatment of schizophrenia, bipolar mania, autistic disorder, and other psychiatric disorders in pediatrics and elderly patients with dementia. Of these 9803 patients, 2687 were patients who received RISPERDAL® while participating in double-blind, placebo-controlled trials. The conditions and duration of treatment with RISPERDAL® varied greatly and included (in overlapping categories) double-blind, fixed- and flexible-dose, placebo- or active-controlled studies and open-label phases of studies, inpatients and outpatients, and short-term (up to 12 weeks) and longer-term (up to 3 years)
Most Helpful Opinions
I think you've faced the side effects after 8 days. I don't think you're going to face anything you've haven't already seen. I've been on it two or three times, and my memory isn't perfect, but as I recall the problems I saw were sleep loss and weight loss (losing the weight that it had put on).
What Girls & Guys Said
Opinion
1Opinion
Weight gain, thoughts of suicide, schizophrenia
Learn more
We're glad to see you liked this post.
You can also add your opinion below!
Most Helpful Opinions